Last reviewed · How we verify

BDD with UDCA — Competitive Intelligence Brief

BDD with UDCA (BDD with UDCA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile acid derivative combination. Area: Hepatology / Gastroenterology.

phase 3 Bile acid derivative combination FXR (farnesoid X receptor) / TGR5 (likely) Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

BDD with UDCA (BDD with UDCA) — Ewha Womans University Mokdong Hospital. BDD (a bile acid derivative) combined with UDCA (ursodeoxycholic acid) enhances bile acid signaling and reduces hepatic inflammation and cholestasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BDD with UDCA TARGET BDD with UDCA Ewha Womans University Mokdong Hospital phase 3 Bile acid derivative combination FXR (farnesoid X receptor) / TGR5 (likely)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bile acid derivative combination class)

  1. Ewha Womans University Mokdong Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BDD with UDCA — Competitive Intelligence Brief. https://druglandscape.com/ci/bdd-with-udca. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: